Cabozantinib as the first step toward postimmunotherapy treatment in hepatocellular carcinoma

Documenti analoghi

• Liver resection is superior to tumor ablation in patients with multifocal hepatocellular carcinoma
  di: Hanna Kakish, et al.
  Pubblicazione: (2024)
• Comment on : “ The platelet‐to‐lymphocyte ratio is a complementary prognostic factor to tumor markers in predicting early recurrence of hepatocellular carcinoma after hepatectomy”
  di: Mu‐Gen Dai, et al.
  Pubblicazione: (2024)
• Comparing barriers to early stage diagnosis of hepatocellular carcinoma between safety net hospitals and academic medical centers: An analysis from the United States Safety‐Net Collaborative
  di: Sophia L. Stylianos, et al.
  Pubblicazione: (2024)
• The role of chemotherapy in the management of pancreatic acinar cell carcinoma
  di: Kimberly P. Woo, et al.
  Pubblicazione: (2024)
• Oncoplastic reconstruction with breast‐conserving treatment versus breast‐conserving treatment alone in the elderly
  di: Menon Ambika, et al.
  Pubblicazione: (2024)